About Hitgen Inc. Company

The company is committed to building a world-class innovative biomedical enterprise. It is headquartered in Chengdu, China, and has subsidiaries in Cambridge, England, and Houston, USA. The company focused on the discovery and optimization of small molecules and new nucleic acid drugs, and focused on building an internationally leading platform for DNA-coding compound library technology (including design, synthesis, screening and expanded application of DEL libraries), and expanded the core technology platform for drug design technology (FBDD/SBDD), oligonucleic acid drug development related technology (STO), and targeted protein degradation related technology (TPD) based on molecular fragments and three-dimensional structural information. The company focuses on the discovery and optimization of small molecules and new nucleic acid drugs, and relies on DEL technology (including design, synthesis, screening and expanded application of DEL libraries), drug design (FBDD/SBDD) technology based on molecular fragments and three-dimensional structural information, oligonucleic acid drug development platform-related technology (STO), targeted protein degradation platform related technology (TPD), and the company's other key new drug development capabilities (pharmaceutical chemistry, computational science/AI, in vitro biological evaluation, pharmacometabolism, analytical chemistry, pharmaceutical research, etc.). The company's main products and services include drug research and development and provision of technical consulting, technology transfer and technical services. Corporate honors: Chengdu Pioneer has been awarded the “CASREGISTRYINNOVATOR” certificate by the Chemical Abstracts Service of the American Chemical Society twice.